A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants

Trial Profile

A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs GSK-2983559 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Jan 2018 Planned End Date changed from 4 Mar 2019 to 22 Apr 2019.
    • 08 Jan 2018 Planned primary completion date changed from 4 Mar 2019 to 22 Apr 2019.
    • 04 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top